PURPOSE: A triazolopyridine derivative is provided to be used in prevention or treatment of a inflammation disease, autoimmune disease, proliferative disease or hyperproliferative diseases, immunologically mediated disease, cancer or tumor that are mediated by an abnormally activated T-lymphocyte, T-lymphocyte, or both of them. CONSTITUTION: A compound represented by Formula 1 and a pharmaceutically-acceptable salt thereof are provided. The compound represented by Formula 1 and a pharmaceutically-acceptable salt thereof are selected from N-(3-(2-(4-(4-methylpiperazine-1-yl)phenylamino)-&lsqb；1,2,4&rsqb；triazolo&lsqb；1,5-a&rsqb；pyridine-8-yloxy)phenyl)acrylamide； N-(3-(2-(3-fluoro-4-(1-methylpiperidine-4-ylamino)phenylamino)-&lsqb；1,2,4&rsqb；triazolo&lsqb；1,5-a&rsqb；pyridine-8-yloxy)phenyl)acrylamide； N-(3-(2-(4-((dimethylamino)methyl)phenylamino)-&lsqb；1,2,4&rsqb；triazolo&lsqb；1,5-a&rsqb；pyridine-8-yloxy)phenyl)acrylamide； N-(3-(2-(4-(4-methylpiperazine-1-carbonyl)phenylamino)-&lsqb；1,2,4&rsqb；triazolo&lsqb；1,5-a&rsqb；pyridine-8-yloxy)phenyl)acrylamide； and N-(3-(2-(4-(4-isopropylpiperazine-1-yl)phenylamino)-&lsqb；1,2,4&rsqb；triazolo&lsqb；1,5-a&rsqb；pyridine-8-yloxy)phenyl)acrylamide.본 발명은 비가역적 타이로신 카이네이즈 활성 억제 효과를 갖는 트리아졸로피리딘 유도체에 관한 것으로, 본 발명의 화합물을 활성성분으로 함유하는 약학 조성물은 염증성 질환, 자가면역 질환, 증식성 질환 또는 과다증식성 질환, 면역학적으로 매개된 질환, 암 또는 종양을 예방하거나 치료하는 효과를 제공한다.
